Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Short Interest Update

Posted by Bonnie Powley on Sep 11th, 2026

Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) saw a large decrease in short interest in the month of August. As of August 31st, there was short interest totaling 340,186 shares, a decrease of 79.3% from the August 15th total of 1,646,299 shares. Based on an average daily trading volume, of 786,030 shares, the short-interest ratio is presently 0.4 days. Currently, 39.3% of the company’s shares are short sold.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Wall Street Zen upgraded Valion Bio, Inc. Common Stock to a “hold” rating in a research report on Saturday, September 5th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a research report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Valion Bio, Inc. Common Stock presently has a consensus rating of “Sell”.

Read Our Latest Stock Report on Valion Bio, Inc. Common Stock

Valion Bio, Inc. Common Stock Stock Down 8.3%

Shares of NASDAQ VBIO opened at $2.20 on Friday. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.86. The company has a market cap of $1.96 million, a P/E ratio of -0.01 and a beta of 1.79. Valion Bio, Inc. Common Stock has a 1 year low of $2.16 and a 1 year high of $80.19. The firm has a 50-day simple moving average of $6.78 and a two-hundred day simple moving average of $16.48.

About Valion Bio, Inc. Common Stock

(Get Free Report)

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.